• 1
    Chassin D,Benifla JL,Delattre C,Fernandez H,Ginisty D,Janneau JL,Prade M,Contesso G,Caillou B,Tournaire M, et al. Identification of genes overexpressed in tumors through preferential expression screening in trophoblasts. Cancer Res 1994; 54: 521723.
  • 2
    Checler F,Emson PC,Vincent JP,Kitabgi P. Inactivation of neurotensin by rat brain synaptic membranes. Cleavage at the Pro10-Tyr11 bond by endopeptidase 24.11 (enkephalinase) and a peptidase different from proline-endopeptidase. J Neurochem 1984; 43: 1295301.
  • 3
    Kenny J. Endopeptidase-24.11: Putative substrates and possible roles. Biochem Soc Trans 1993; 21: 6638.
  • 4
    Shipp MA,Tarr GE,Chen CY,Switzer SN,Hersh LB,Stein H,Sunday ME,Reinherz EL. CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci USA 1991; 88: 106626.
  • 5
    Chu PG,Chang KL,Weiss LM,Arber DA. Immunohistochemical detection of CD10 in paraffin sections of hematopoietic neoplasms: a comparison with flow cytometry detection in 56 cases. Appl Immunohistochem Mol Morphol 2000; 8: 25762.
  • 6
    Burns DM,Walker B,Gray J,Nelson J. Breast cancer cell associated endopeptidase EC 24.11 modulates proliferative response to bombesin. Br J Cancer 1999; 79: 21420.
  • 7
    Bunn PA,Jr,Helfrich BA,Brenner DG,Chan DC,Dykes DJ,Cohen AJ,Miller YE. Effects of recombinant neutral endopeptidase (EC on the growth of lung cancer cell lines in vitro and in vivo. Clin Cancer Res 1998; 4: 284958.
  • 8
    Erdos EG,Schulz WW,Gafford JT,Defendini R. Neutral metalloendopeptidase in human male genital tract. Comparison to angiotensin I-converting enzyme. Lab Invest 1985; 52: 43747.
  • 9
    Renneberg H,Albrecht M,Kurek R,Krause E,Lottspeich F,Aumuller G,Wilhelm B. Identification and characterization of neutral endopeptidase (EC 3. 4. 24. 11) from human prostasomes-Localization in prostatic tissue and cell lines. Prostate 2001; 46: 17383.
  • 10
    Sunday ME,Hua J,Torday JS,Reyes B,Shipp MA. CD10/neutral endopeptidase 24.11 in developing human fetal lung. Patterns of expression and modulation of peptide-mediated proliferation. J Clin Invest 1995; 90: 251725.
  • 11
    Soleilhac JM,Lucas E,Beaumont A,Turcaud S,Michel JB,Ficheux D,Fournie-Zaluski MC,Roques BP. A 94-kDa protein, identified as neutral endopeptidase-24.11, can inactivate atrial natriuretic peptide in the vascular endothelium. Mol Pharmacol 1992; 41: 60914.
  • 12
    Pekonen F,Nyman T,Rutanen EM. Differential expression of mRNAs for endothelin-related proteins in human endometrium, myometrium and leiomyoma. Mol Cell Endocrinol 1994; 103: 16570.
  • 13
    King KA,Hua J,Torday JS,Drazen JM,Graham SA,Shipp MA,Sunday ME. CD10/neutral endopeptidase 24.11 regulates fetal lung growth and maturation in utero by potentiating endogenous bombesin-like peptides. J Clin Invest 1993; 91: 196973.
  • 14
    Moody TW,Mayr CA,Gillespie TJ,Davis TP. Neurotensin is metabolized by endogenous proteases in prostate cancer cell lines. Peptides 1998; 19: 2538.
  • 15
    Gohring B,Holzhausen HJ,Meye A,Heynemann H,Rebmann U,Langner J,Riemann D. Endopeptidase 24.11/CD10 is downregulated in renal cell cancer. Int J Mol Med 1998; 2: 40914.
  • 16
    Koiso K,Akaza H,Ohtani M,Miyanaga N,Aoyagi K. A new tumor marker for bladder cancer. Int J Urol 1994; 1: 336.
  • 17
    Sato Y,Itoh F,Hinoda Y,Ohe Y,Nakagawa N,Ueda R,Yachi A,Imai K. Expression of CD10/neutral endopeptidase in normal and malignant tissues of the human stomach and colon. J Gastroenterol 1996; 31: 1217.
  • 18
    Cohen AJ,Bunn PA,Franklin W,Magill-Solc C,Hartmann C,Helfrich B,Gilman L,Folkvord J,Helm K,Miller YE. Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. Cancer Res 1996; 56: 8319.
  • 19
    Pekonen F,Nyman T,Ammala M,Rutanen EM. Decreased expression of messenger RNAs encoding endothelin receptors and neutral endopeptidase 24.11 in endometrial cancer. Br J Cancer 1995; 71: 5963.
  • 20
    Papandreou CN,Usmani B,Geng Y,Bogenrieder T,Freeman R,Wilk S,Finstad CL,Reuter VE,Powell CT,Scheinberg D,Magill C,Scher HI, et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998; 4: 507.
  • 21
    Shipp MA,Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood 1993; 82: 105270.
  • 22
    Gee NS,Bowes MA,Buck P,Kenny AJ. An immunoradiometric assay for endopeptidase-24.11 shows it to be a widely distributed enzyme in pig tissues. Biochem J 1985; 228: 11926.
  • 23
    Notohara, K,Hamazaki S,Tsukayama C,Nakamoto S,Kawabata K,Mizobuchi K,Sakamoto K,Okada S. Solid-pseudopapillary tumor of the pancreas: immunohistochemical localization of neuroendocrine markers and cd10. Am J Surg Pathol 2000; 24: 136171.
  • 24
    Chen C,Jing W,Gulati P,Vargas H,French SW. Melanocytic differentiation in a solid pseudopapillary tumor of the pancreas. J Gastroenterol 2004; 39: 57983.
  • 25
    Chomczynski P,Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 1569.
  • 26
    Elsasser HP,Lehr U,Agricola B,Kern HF. Establishment and characterisation of two cell lines with different grade of differentiation derived from one primary human pancreatic adenocarcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol 1992; 61: 295306.
  • 27
    Nishimura N,Saito S,Kubota Y,Moto-o N,Taguchi K,Yamazaki K,Watanabe A,Sasaki H. Newly established human pancreatic carcinoma cell lines and their lectin binding properties. Int J Pancreatol 1993; 13: 3141.
  • 28
    Takamori H,Hiraoka T,Yamamoto T. Expression of tumor-associated carbohydrate antigens correlates with hepatic metastasis of pancreatic cancer: clinical and experimental studies. Hepatogastroenterology 1996; 43: 74855.
  • 29
    Mullins TD,Kern HF,Metzgar RS. Ultrastructural differentiation of sodium butyrate-treated human pancreatic adenocarcinoma cell lines. Pancreas 1991; 6: 57887.
  • 30
    Tsutsumi S,Kuwano H,Morinaga N,Shimura T,Asao T. Animal model of para-aortic lymph node metastasis. Cancer Lett 2001; 169: 7785.
  • 31
    Elsasser HP,Lehr U,Agricola B,Kern HF. Structural analysis of a new highly metastatic cell line PaTu 8902 from a primary human pancreatic adenocarcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol 1993; 64: 2017.
  • 32
    D'Adamio L,Shipp MA,Masteller EL,Reinherz EL. Organization of the gene encoding common acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): multiple miniexons and separate 5′ untranslated regions. Proc Natl Acad Sci USA 1989; 86: 71037.
  • 33
    Ishimaru F,Mari B,Shipp MA. The type 2 CD10/neutral endopeptidase 24.11 promoter: functional characterization and tissue-specific regulation by CBF/NF-Y isoforms. Blood 1997; 89: 413645.
  • 34
    Usmani BA,Shen R,Janeczko M,Papandreou CN,Lee WH,Nelson WG,Nelson JB,Nanus DM. Methylation of the neutral endopeptidase gene promoter in human prostate Cancers. Clin Cancer Res 2000; 1664: 166470.
  • 35
    Chorvath B,Sedlak J,Duraj J,Pleskova I,Dubovsky P,Augustinova M,Doxiadis I,Grosse-Wilde H. Modulation of CALLA (CD10) antigen on cultured ALL (REH) cells: effect of various modulators. Neoplasma 1990; 37: 60918.
  • 36
    Tharaux PL,Stefanski A,Ledoux S,Soleilhac JM,Ardaillou R,Dussaule JC. EGF and TGF-β regulate neutral endopeptidase expression in renal vascular smooth muscle cells. Am J Physiol Cell Physiol 1997; 272: 183643.
  • 37
    Casey ML,Smith JW,Nagai K,MacDonald PC. Transforming growth factor-β 1 inhibits enkephalinase (EC gene expression in human endometrial stromal cells and sex skin fibroblasts in culture. J Clin Endocrinol Metab 1993; 77: 14450.
  • 38
    van der Velden VH,Naber BA,van der Spoel P,Hoogsteden HC,Versnel MA. Cytokines and glucocorticoids modulate human bronchial epithelial cell peptidases. Cytokine 1998; 10: 5565.
  • 39
    Ishii E,Greaves A,Grunberger T,Freedman MH,Letarte M. Tumor formation by a human pre-B leukemia cell line in scid mice is enhanced by matrigel and is associated with induction of CD10 expression. Leukemia 1995; 9: 17584.
  • 40
    Gaschott T,Maassen CU,Stein J. Tributyrin, a butyrate precursor, impairs growth and induces apoptosis and differentiation in pancreatic cancer cells. Anticancer Res 2001; 21: 281519.
  • 41
    Egawa N,Maillet B,Van Damme B,De Greve J,Kloppel G. Differentiation of pancreatic carcinoma induced by retinoic acid or sodium butyrate: a morphological and molecular analysis of four cell lines. Virchows Arch 1996; 429: 5968.
  • 42
    Corra S,Kazakoff K,Mogaki M,Cano M,Pour PM. Modification of antigen expression in human and hamster pancreatic cancer cell lines induced by sodium butyrate. Teratog Carcinog Mutagen 1993; 13: 199215.
  • 43
    Bloom EJ,Siddiqui B,Hicks JW,Kim YS. Effect of sodium butyrate, a differentiating agent, on cell surface glycoconjugates of a human pancreatic cell line. Pancreas 1989; 4: 5964.
  • 44
    Carvalho KM,De Laurenzi V,Melino G,Cohen P. Modulation of a novel thermolysin-like metallo-endopeptidase activity during retinoic acid-induced differentiation of human neuroectodermal tumor cell lines. Biochem Biophys Res Commun 1993; 191: 1729.
  • 45
    Hayashi K,Goodison S,Urquidi V,Tarin D,Lotan R,Tahara E. Differential effects of retinoic acid on the growth of isogenic metastatic and non-metastatic breast cancer cell lines and their association with distinct expression of retinoic acid receptor β isoforms 2 and 4. Int J Oncol 2003; 22: 6239.
  • 46
    Zuco V,Supino R,Righetti S,Cleris L,Marchesi E,Gambacorti-Passerini C,Formelli F. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett 2002; 175: 1725.
  • 47
    Joseph J,Mudduluru G,Antony S,Vashistha S,Ajitkumar P,Somasundaram K. Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene 2001; 23: 630415.
  • 48
    Kouraklis G,Theocharis S. Histone deacetylase inhibitors and anticancer therapy. Curr Med Chem Anticancer Agents 2002; 2: 47784.
  • 49
    Jung M. Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem 2001; 8: 150511.
  • 50
    Sumitomo M,Milowsky MI,Shen R,Navarro D,Dai J,Asano T,Hayakawa M,Nanus DM. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor Akt cell survival pathway. Cancer Res 2001; 61: 32948.
  • 51
    Sumitomo M,Shen R,Walburg M,Dai J,Geng Y,Navarro D,Boileau G,Papandreou CN,Giancotti FG,Knudsen B,Nanus DM. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest 2000; 106: 1399407.
  • 52
    Sumitomo M,Iwase A,Zheng R,Navarro D,Kaminetzky D,Shen R,Georgescu MM,Nanus DM. Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cells 2004; 5: 6778.
  • 53
    Einzhamer DA,Xu ZQ. Betulinic acid: a promising anticancer candidate. Drugs 2004; 7: 35973.